ClarityX DNA Review 2026: Cost, Panel, and How It Compares

Verdict: ClarityX is a focused, self-pay pharmacogenomic (PGx) test best for patients with a prescribing conversation lined up with a clinician. As of August 2026, Mindwell lists at $399 and Max Rx at $499 — both genotype the same 39-gene panel, processed at a CLIA-certified, CAP-accredited lab from an at-home collection kit ClarityX describes as both a cheek swab and a saliva sample. If you want medication-response guidance to bring into an appointment, ClarityX is worth a look. If you want ancestry, traits, or a self-prescribing shortcut, it is the wrong product — for wellness and nutrition, ClarityX sells separate Thrive and Clear kits, not covered in depth here.

PGx testing earns its keep when it helps a clinician make a better prescribing call. It is much weaker as a do-it-yourself answer, and the FDA has been explicit that genetic results are one input among many in a prescribing decision. See ClarityX pricing for current checkout figures before you buy.

Key Takeaways

• ClarityX sells four consumer kits: Mindwell and Max Rx for pharmacogenomics, plus Thrive and Clear, separate nutrition/wellness kits not covered by this review.
• August 2026 list pricing: Mindwell $399, Max Rx $499. ClarityX’s 25%-off CLARITY25 code is a dated Summer Sale campaign ending 08/24, 2026 — don’t treat the promo price as the standing one. HSA/FSA accepted.
• Mindwell and Max Rx genotype the identical 39 genes. The difference is report scope: Mindwell interprets 120+ mental-health medications, Max Rx interprets 285+ medications across 20+ therapeutic areas. Only a subset of those drugs have actionable FDA pharmacogenomic labeling or CPIC prescribing guidance.
• The panel highlights core CYP450 genes (CYP2D6, CYP2C19, CYP2C9, CYP3A4/5, CYP1A2, CYP2B6) plus high-value non-CYP markers like SLCO1B1, VKORC1, the TPMT/NUDT15 pair, and HLA-B*15:02, several backed by CPIC guidance for specific gene-drug pairs. SLC6A4 is no longer on the published panel.
• ClarityX has no FDA marketing authorization for its test. Like most clinical PGx panels it runs under CLIA rather than as an FDA-cleared device; ClarityX does not publish an explicit “laboratory-developed test” statement, so treat that label as a reasonable inference, not a claim ClarityX makes itself.
• Samples are processed at a CLIA-certified, CAP-accredited lab (ClarityX does not publish the lab’s name, location, or CLIA number). Results are typically available 5–10 business days after lab receipt for Mindwell and Max Rx.
• ClarityX does not accept health insurance, including Medicare, in any form. Medicare’s own PGx coverage rules (NCD 90.1, LCD L39073) apply to clinician-ordered, billed testing generally — they don’t change ClarityX’s self-pay-only posture. Every buyer pays out of pocket.

How ClarityX Works

A PGx test reads specific genetic variants (inherited differences in your DNA) that influence how your body processes or responds to a medication. Some variants slow a drug down, some speed it up, and a few flag a higher side-effect risk. NHGRI and MedlinePlus both note that PGx results are one input alongside health history, lifestyle, and other medications.

Collection is an at-home DNA collection kit — but ClarityX’s own site describes it inconsistently. The FAQ calls it a saliva sample with saliva-specific collection guidance, while the how-it-works steps on the same pages describe a simple cheek swab. Either way, no clinic visit or blood draw is required; you activate the kit online and mail the sample back in the prepaid packaging. Results are typically available 5–10 business days after the lab receives the sample, with outbound shipping (3–6 business days) on top of that. ClarityX ships to the United States and Canada only.

The report is organized around drugs, not genes. For each medication in scope, ClarityX assigns a category (use as directed, use with caution, or consider alternatives) plus dosing guidance and side-effect flags. The value is the prescribing conversation it triggers, not the genotype itself.

What ClarityX Tests: Genes and Drug Interactions

The most useful question for any PGx test is which genes it reads, and here is the headline finding of this review: Mindwell and Max Rx publish byte-identical “Genes Tested” sections. Both kits genotype the same 39 genes across six categories — drug metabolism (10 genes, including the CYP450 family), transport and clearance (6), response signals for brain/mood/pain (7), safety flags (8), risk management (6), and nutrient processing (2, including MTHFR). The $100 gap between the two kits buys a broader interpretation report — more medications covered — not a bigger panel. ClarityX also lists additional metabolism, transporter, safety, and risk-management genes, including DPYD, NUDT15, HLA-A31:01, HLA-B57:01, HLA-B*58:01, MT-RNR1, UGT1A1, CYP2C8, CES1, and NAT2, among others. Confirm the exact gene and variant list in your kit’s sample report before ordering.

CYP450 drug-metabolizing enzymes

• CYP2D6: metabolizes about a quarter of clinically used drugs, including many SSRIs, tricyclics, beta-blockers, opioids, and antipsychotics. Variants can produce poor metabolism (the drug builds up) or ultra-rapid metabolism (the drug clears before it works).
• CYP2C19: relevant to several drugs, including citalopram, escitalopram, sertraline, clopidogrel, and proton-pump inhibitors. Actionability depends on the specific CYP2C19-drug pair, not the gene alone.
• CYP2C9: warfarin, NSAIDs, phenytoin. Variants can substantially shift safe warfarin dosing.
• CYP3A4 / CYP3A5: statins, immunosuppressants, many calcium-channel blockers and psychiatric medications.
• CYP2B6: bupropion, efavirenz, methadone.
• CYP1A2: caffeine, clozapine, olanzapine, theophylline.

Non-CYP variants with high prescribing weight

• SLCO1B1: statin-transporter gene; variants raise risk of statin-induced muscle injury (simvastatin in particular).
• VKORC1: warfarin target enzyme; pairs with CYP2C9 under Medicare’s NCD 90.1.
• TPMT and NUDT15: together, these flag severe bone-marrow suppression risk with thiopurine drugs like azathioprine and mercaptopurine. Current prescribing guidance pairs the two genes rather than relying on TPMT alone, and ClarityX lists both on its public panel.
• HLA-B15:02 and HLA-A31:01: HLA-B15:02 flags Stevens-Johnson syndrome risk with carbamazepine in genetically at-risk Asian populations, including Han Chinese, Thai, Malaysian, Taiwanese, and other Southeast Asian groups, with intermediate prevalence in some South Asian populations. HLA-A31:01 is also relevant to carbamazepine hypersensitivity and shows up more broadly across populations, so it is worth checking even if HLA-B*15:02 is negative.

Markers to read with caution

ClarityX’s current panel includes HTR2A, HTR2C, DRD2, GRIK4, ADRA2A, COMT, APOE, and MTHFR. (SLC6A4, the serotonin transporter gene, does not appear anywhere on ClarityX’s current published gene list for either kit.) The 2023 CPIC antidepressant guideline says existing pharmacodynamic data do not support clinical use of HTR2A for SSRI selection, and CPIC has made the same point about the other serotonergic response markers on this panel. ACMG reaffirmed in 2020 that common MTHFR polymorphism testing lacks evidence for routine clinical use. If your report leans on those markers, ask your clinician to weight them accordingly.

Mindwell and Max Rx read the same 39-gene panel — there is no “focused subset” versus “broader panel” distinction in the DNA tested. What changes at the Max Rx tier is the interpretation report: it expands from 120+ mental-health medications to 285+ medications across psychiatry, cardiology, pain management, endocrinology, gastroenterology, gynecology, immunology, infectious disease, neurology, oncology, and more. Only some of those drugs have actionable FDA pharmacogenomic labeling or CPIC guidance.

Cost and What’s Included

Pricing verified from ClarityX product pages, August 21, 2026. List prices are the durable numbers — ClarityX’s 25%-off CLARITY25 code is a dated Summer Sale campaign that ends 08/24, 2026, not a standing discount.

Both kits include the at-home collection device, prepaid return shipping, lab processing at a CLIA-certified, CAP-accredited facility, the patient-facing report, and review of the order by a network physician licensed in one of all 50 states — no prescriber of your own is required to buy. A consult with a pharmacist certified in pharmacogenetics is available, but it costs extra; ClarityX’s FAQ states the pharmacist consultation “is available for an additional cost” and is booked through the patient portal after results are in. (ClarityX’s About Us page describes the consult as included, which conflicts with the FAQ — treat the FAQ as the more specific, more recent statement.)

HSA and FSA cards are accepted, and ClarityX provides an itemized receipt for reimbursement. ClarityX does not accept health insurance — its own FAQ states this plainly, including for Medicare. Every order is self-pay; if your plan covers a billed alternative like GeneSight, Tempus nP, or Genomind’s provider-ordered route, that will usually beat ClarityX’s out-of-pocket price. See ClarityX pricing for current checkout figures.

Insurance and Medicare Coverage

ClarityX settles this question directly: “ClarityX® does not accept health insurance.” That covers Medicare too — there is no direct Medicare billing path for a ClarityX kit. Every order is self-pay.

Medicare’s PGx coverage rules exist, but they apply to the modality, not to ClarityX. NCD 90.1 covers CYP2C9/VKORC1 testing for warfarin response only under coverage-with-evidence-development criteria: enrollment in a qualifying prospective randomized clinical study and fewer than five days of warfarin in the relevant anticoagulation regimen. It does not replace standard INR monitoring. Broader PGx scenarios fall under MolDX LCD L39073 (and parallel LCDs in other Medicare Administrative Contractor jurisdictions), which ties coverage to a change in therapy based on the FDA drug label, an FDA warning, or a CPIC Level A/B gene-drug interaction. Even where Medicare would pay under those policies, it pays a billing laboratory for a clinician-ordered test — and because ClarityX doesn’t bill insurance at all, a self-purchased ClarityX kit is out of pocket regardless of whether you’d otherwise qualify.

Commercial insurance. ClarityX does not bill commercial insurers either. Competitors that do bill — GeneSight, Genomind for its Medicare Part B provider-ordered test, Tempus nP, and OneOme — are the relevant comparison if you have coverage worth using.

HSA / FSA. Both kits are payable with HSA/FSA funds, and ClarityX provides an itemized receipt for reimbursement claims. Payment plans of up to four installments are also available through Shop Pay at checkout.

Self-pay. The only path for a ClarityX kit. List prices ($399 Mindwell, $499 Max Rx) are the durable numbers; the current 25%-off promo code is a dated campaign, not a standing discount.

ClarityX vs. GeneSight vs. Genomind vs. Tempus nP vs. OneOme {#comparison}

The PGx category has several serious consumer-and-clinician brands. The shape of the decision is usually price vs. payer footprint vs. who actually reviews the report.

Competitor prices sourced from each vendor’s own posted pages, accessed August 21, 2026.

GeneSight is the brand to beat on insurance footprint. ClarityX wins on panel breadth at the Max Rx tier and on self-pay checkout clarity, but genotypes fewer genes than Genomind or OneOme — its edge is a bigger interpreted-drug list, not more DNA. Genomind buys the deepest self-pay panel at the highest self-pay price, with a genetic-counselor consult included. Tempus nP and OneOme both require a clinician to order, which is the trade-off for their insurance footprint.

For mental-health prescribing with GeneSight coverage, start there. For multi-specialty prescribing across cardiology, pain, or oncology without a clinician willing to order Tempus nP or OneOme, Max Rx covers more drugs per dollar.

Provider Portal and EHR Integration

ClarityX positions itself as clinician-facing, and the provider experience differs from a 23andMe-style consumer dashboard. Through the provider portal, clinicians order kits, review drug-by-drug recommendations, see dosing-modifier guidance, and flag drug-drug-gene interactions across a patient’s medication list.

The provider report shows three columns: medications in the regimen, the predicted phenotype for the relevant gene (e.g., CYP2D6 intermediate metabolizer), and a categorized recommendation. Read each recommendation through the lens of its underlying evidence: some gene-drug pairs sit on direct FDA labeling or CPIC guidance, while others are lower-evidence signals that still need clinician judgment. The patient-facing version is a simpler read of the same data.

ClarityX does not publish an Epic App Orchard or Oracle Health (Cerner) integration listing as of August 2026, and independent EHR-integration confirmation was not available at review time. Reports deliver through the ClarityX portal and download as PDF for upload to the chart. The provider-onboarding flow handles NPI verification before a new clinician orders, so confirm with your prescriber before buying a kit yourself.

Lab and Certification

ClarityX states its samples are processed at a CAP-accredited and CLIA-certified reference lab. CLIA is the federal certification floor for diagnostic labs in the U.S.; CAP accreditation from the College of American Pathologists is the standard quality layer on top. Both are baseline expectations for any 2026 PGx test. ClarityX also badges itself “HIPAA certified” on product pages — there is no such thing as HIPAA certification (HIPAA is a compliance obligation, not a certificate any body issues), so read that badge as marketing language, not a credential.

ClarityX product pages do not publish the processing lab’s name, location, CLIA number, or CAP certificate ID. The About Us page only says the company “utilizes state-of-the-art CLIA-certified and CAP-accredited laboratories” without naming them. Ask customer service for those details before purchase if you need documentation (for instance, to submit the result to a benefits administrator or clinical trial sponsor). The merchant accreditation badge alone is not a verifiable certification record.

Regulatory status matters separately from lab accreditation. ClarityX does not publish an explicit “laboratory-developed test” (LDT) statement, so that designation is unverified from ClarityX’s own site — though the inference is reasonable, since a CLIA-run PGx panel with no FDA marketing authorization typically is an LDT. What’s confirmed either way: ClarityX’s test is not FDA-approved, FDA-authorized, or FDA-cleared. The FDA’s pharmacogenomic biomarker tables apply to drug labels, not to ClarityX’s product, and the FDA has previously warned other PGx labs (Inova Genomics, April 2019) about marketing claims that go beyond what drug labeling supports.

Privacy, HIPAA, and Data Handling

ClarityX collects three categories of data: personal information at checkout, medication information at sample registration, and sample-derived genetic data from the lab. The current privacy policy (effective January 31, 2025, unchanged since our last review) states that test kits containing DNA are destroyed once genetic information is produced. On selling data, the policy is more careful than it sounds at first read: it says ClarityX / Precision Sciences “will not sell, lease, or rent your identifiable individual information to any third party without your explicit consent.” That’s a no-sale-without-consent commitment scoped to identifiable information, not an absolute promise — don’t read it as “ClarityX never sells your data.” (ClarityX’s FAQ states the no-sale point more absolutely than the policy itself does; where the two conflict, the policy governs.)

PGx data sits at an awkward legal seam, so the protections you get depend on the path:

• Clinician-ordered (HIPAA path). If your prescriber orders through the provider portal and the result enters your medical record, HIPAA covers the data as protected health information. The clinician’s practice is the covered entity, and HIPAA’s access, correction, and breach-notification rules apply.
• Direct-to-consumer (consumer-privacy path). If you buy a kit yourself and the result never routes through a HIPAA-covered clinician, HIPAA generally does not apply — even though ClarityX says it follows HIPAA requirements. Whether you actually get HIPAA’s patient rights depends on whether the result lands in a covered entity’s record, which for a self-purchased kit it may not. State-level genetic privacy laws and ClarityX’s own policy become the controlling framework.

The policy does not publish a specific retention period for your derived genetic data (only that the physical kit is destroyed once results are produced), a research opt-in or opt-out, a vendor-sharing list, or a one-click deletion right — it only says you can request deletion, with no stated turnaround. If those details matter, ask in writing before submitting your sample.

Pros and Cons

Who Should Buy It

If a ClarityX result raises questions you can’t resolve with your prescriber alone, a genetic counselor can help you weigh the lower-evidence markers on the panel against the ones with real CPIC or FDA backing. ClarityX makes the most sense for:

• patients working with a clinician on medication optimization
• people with a history of poor response or hard side effects on prior prescriptions
• buyers who want a PGx-focused product rather than a broad ancestry kit
• patients paying with HSA or FSA who want a clear self-pay path

It makes less sense for:

• anyone shopping for ancestry, traits, or wellness reports
• patients expecting a diagnosis from the report
• buyers planning to adjust their own medications without clinical input
• patients with strong commercial insurance for PGx, where GeneSight is usually cheaper out-of-pocket

FAQ

Is ClarityX legit?

Yes. ClarityX uses a CLIA-certified, CAP-accredited reference lab and operates a clinician network in all 50 states. It has no FDA marketing authorization; it runs under CLIA rather than as an FDA-cleared device, which is the standard regulatory posture for most clinical PGx products (ClarityX itself does not publish an explicit “laboratory-developed test” statement, so treat that specific label as inference rather than a claim ClarityX makes). The major gene-drug pairs on the panel are backed by CPIC guidelines and FDA drug labeling; others are lower-evidence signals. Your result is one input into a prescribing decision, not the decision itself.

What’s the actual difference between Mindwell and Max Rx?

Nothing in the DNA. Both kits genotype the same 39 published genes. Mindwell’s report interprets that genotype against 120+ mental-health medications; Max Rx’s report interprets the same genotype against 285+ medications across 20+ therapeutic areas. You’re paying the extra $100 for a broader drug report, not a bigger panel.

How much does ClarityX cost in 2026?

Mindwell lists at $399 and Max Rx at $499 as of August 2026. ClarityX’s current 25%-off CLARITY25 code is a dated Summer Sale campaign ending 08/24, 2026 — treat the list prices as the durable numbers rather than the promo. HSA and FSA cards are accepted.

Is ClarityX covered by insurance?

No. ClarityX states plainly that it does not accept health insurance, including Medicare. NCD 90.1 and LCD L39073 govern Medicare’s coverage of PGx testing in general — NCD 90.1 covers CYP2C9/VKORC1 warfarin testing only under coverage-with-evidence-development criteria, and LCD L39073 covers broader clinician-ordered, billed testing — but neither creates a path to Medicare paying for a self-purchased ClarityX kit, because ClarityX doesn’t bill any insurer at all.

Is the pharmacist consult included?

No. ClarityX’s FAQ states the pharmacist consultation “is available for an additional cost” and is booked through the patient portal after your results are in. That conflicts with older marketing language suggesting it’s bundled; confirm the current price before booking.

ClarityX vs. GeneSight: which is better?

GeneSight has the longer payer footprint; if your insurer covers it, GeneSight’s $330 self-pay rate (or lower with insurance) usually lands at a lower out-of-pocket cost for a mental-health decision, but it requires a clinician to order it. ClarityX Max Rx covers a wider drug list at a clearer self-pay checkout, which matters more if your medication question spans cardiology, pain, or oncology and you don’t have a prescriber willing to order a competitor.

How long do ClarityX results take?

Typically 5 to 10 business days after the lab receives the sample for Mindwell and Max Rx. Outbound shipping adds another 3 to 6 business days.

Bottom Line

ClarityX is a credible self-pay pharmacogenomic test. The biggest thing to understand before buying is that Mindwell and Max Rx read the identical 39-gene panel — the $100 gap between them buys a broader medication report, not more DNA. The lab is CLIA-certified and CAP-accredited, though ClarityX doesn’t publish the lab’s name or CLIA number, and it does not accept insurance of any kind. The ceiling is the same as every PGx test: the report only helps as much as the prescribing conversation that follows it.

If you have a clinician ready to use the results, Mindwell at $399 is a fair price for a psychiatry-focused report, and Max Rx at $499 covers the wider medication list on the same panel. If your insurance covers GeneSight, Tempus nP, or a provider-ordered Genomind test, run those numbers first — they’ll usually beat ClarityX’s self-pay price. Whatever you buy, do not self-prescribe off the report.